J Control Release: 在去势难治性前列腺癌中,脂质与寡核苷酸偶联可以提高细胞吞噬和反义-TCTP的效率

2017-05-09 AlexYang MedSci原创

翻译控制肿瘤蛋白(TCTP)与细胞生长、细胞周期进程、恶性转化和细胞凋亡的抑制等大量重要细胞学过程相关。因此,TCTP是一个目前被作为一个潜在的治疗几种癌症的靶点,包括前列腺癌、乳腺癌和肺癌。之前,有报道指出,TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。最近,研究人员开发了TCTP反义寡核苷酸链(ASOs)来尝试抑制TCTP的表达。然而,这些ASOs的细胞内传递

翻译控制肿瘤蛋白(TCTP)与细胞生长、细胞周期进程、恶性转化和细胞凋亡的抑制等大量重要细胞学过程相关。因此,TCTP是一个目前被作为一个潜在的治疗几种癌症的靶点,包括前列腺癌、乳腺癌肺癌。之前,有报道指出,TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。

最近,研究人员开发了TCTP反义寡核苷酸链(ASOs)来尝试抑制TCTP的表达。然而,这些ASOs的细胞内传递和沉默活性仍旧是一个挑战,并且还要依赖与转染药物和传递系统的使用。研究发现,在体内和体外试验中,缺乏另加转染药物的情况下,脂类修饰的ASO(LASOs)提高了抑制TCTP表达的渗透性和效率。通过巨胞饮,将TCTP-LASO转染可以导致快速的和持久的内部化、TCTP下调和细胞运动性的减弱。最后,研究人员指出,脂类修饰在CRPC异种种植模型中可以推迟肿瘤进展,并且没有显著地毒性作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647796, encodeId=4041164e7965b, content=<a href='/topic/show?id=a0d954329f' target=_blank style='color:#2F92EE;'>#CTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5432, encryptionId=a0d954329f, topicName=CTP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3223492864, createdName=whlxd, createdTime=Fri May 12 21:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804969, encodeId=8e1b180496932, content=<a href='/topic/show?id=5eb0e782981' target=_blank style='color:#2F92EE;'>#细胞吞噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77829, encryptionId=5eb0e782981, topicName=细胞吞噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sat Sep 23 13:01:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700410, encodeId=945b1e004107b, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri May 12 12:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945609, encodeId=e5d61945609d4, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Nov 08 19:01:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394631, encodeId=30a61394631ef, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528343, encodeId=2b03152834326, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196325, encodeId=99f01963259e, content=TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Wed May 10 22:07:46 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-12 whlxd
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647796, encodeId=4041164e7965b, content=<a href='/topic/show?id=a0d954329f' target=_blank style='color:#2F92EE;'>#CTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5432, encryptionId=a0d954329f, topicName=CTP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3223492864, createdName=whlxd, createdTime=Fri May 12 21:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804969, encodeId=8e1b180496932, content=<a href='/topic/show?id=5eb0e782981' target=_blank style='color:#2F92EE;'>#细胞吞噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77829, encryptionId=5eb0e782981, topicName=细胞吞噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sat Sep 23 13:01:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700410, encodeId=945b1e004107b, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri May 12 12:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945609, encodeId=e5d61945609d4, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Nov 08 19:01:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394631, encodeId=30a61394631ef, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528343, encodeId=2b03152834326, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196325, encodeId=99f01963259e, content=TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Wed May 10 22:07:46 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647796, encodeId=4041164e7965b, content=<a href='/topic/show?id=a0d954329f' target=_blank style='color:#2F92EE;'>#CTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5432, encryptionId=a0d954329f, topicName=CTP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3223492864, createdName=whlxd, createdTime=Fri May 12 21:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804969, encodeId=8e1b180496932, content=<a href='/topic/show?id=5eb0e782981' target=_blank style='color:#2F92EE;'>#细胞吞噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77829, encryptionId=5eb0e782981, topicName=细胞吞噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sat Sep 23 13:01:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700410, encodeId=945b1e004107b, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri May 12 12:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945609, encodeId=e5d61945609d4, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Nov 08 19:01:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394631, encodeId=30a61394631ef, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528343, encodeId=2b03152834326, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196325, encodeId=99f01963259e, content=TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Wed May 10 22:07:46 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647796, encodeId=4041164e7965b, content=<a href='/topic/show?id=a0d954329f' target=_blank style='color:#2F92EE;'>#CTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5432, encryptionId=a0d954329f, topicName=CTP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3223492864, createdName=whlxd, createdTime=Fri May 12 21:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804969, encodeId=8e1b180496932, content=<a href='/topic/show?id=5eb0e782981' target=_blank style='color:#2F92EE;'>#细胞吞噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77829, encryptionId=5eb0e782981, topicName=细胞吞噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sat Sep 23 13:01:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700410, encodeId=945b1e004107b, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri May 12 12:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945609, encodeId=e5d61945609d4, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Nov 08 19:01:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394631, encodeId=30a61394631ef, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528343, encodeId=2b03152834326, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196325, encodeId=99f01963259e, content=TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Wed May 10 22:07:46 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-11-08 xsm918
  5. [GetPortalCommentsPageByObjectIdResponse(id=1647796, encodeId=4041164e7965b, content=<a href='/topic/show?id=a0d954329f' target=_blank style='color:#2F92EE;'>#CTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5432, encryptionId=a0d954329f, topicName=CTP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3223492864, createdName=whlxd, createdTime=Fri May 12 21:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804969, encodeId=8e1b180496932, content=<a href='/topic/show?id=5eb0e782981' target=_blank style='color:#2F92EE;'>#细胞吞噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77829, encryptionId=5eb0e782981, topicName=细胞吞噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sat Sep 23 13:01:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700410, encodeId=945b1e004107b, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri May 12 12:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945609, encodeId=e5d61945609d4, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Nov 08 19:01:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394631, encodeId=30a61394631ef, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528343, encodeId=2b03152834326, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196325, encodeId=99f01963259e, content=TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Wed May 10 22:07:46 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1647796, encodeId=4041164e7965b, content=<a href='/topic/show?id=a0d954329f' target=_blank style='color:#2F92EE;'>#CTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5432, encryptionId=a0d954329f, topicName=CTP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3223492864, createdName=whlxd, createdTime=Fri May 12 21:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804969, encodeId=8e1b180496932, content=<a href='/topic/show?id=5eb0e782981' target=_blank style='color:#2F92EE;'>#细胞吞噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77829, encryptionId=5eb0e782981, topicName=细胞吞噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sat Sep 23 13:01:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700410, encodeId=945b1e004107b, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri May 12 12:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945609, encodeId=e5d61945609d4, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Nov 08 19:01:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394631, encodeId=30a61394631ef, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528343, encodeId=2b03152834326, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196325, encodeId=99f01963259e, content=TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Wed May 10 22:07:46 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-11 freve
  7. [GetPortalCommentsPageByObjectIdResponse(id=1647796, encodeId=4041164e7965b, content=<a href='/topic/show?id=a0d954329f' target=_blank style='color:#2F92EE;'>#CTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5432, encryptionId=a0d954329f, topicName=CTP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3223492864, createdName=whlxd, createdTime=Fri May 12 21:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804969, encodeId=8e1b180496932, content=<a href='/topic/show?id=5eb0e782981' target=_blank style='color:#2F92EE;'>#细胞吞噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77829, encryptionId=5eb0e782981, topicName=细胞吞噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sat Sep 23 13:01:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700410, encodeId=945b1e004107b, content=<a href='/topic/show?id=2f93465966d' target=_blank style='color:#2F92EE;'>#寡核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46596, encryptionId=2f93465966d, topicName=寡核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri May 12 12:01:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945609, encodeId=e5d61945609d4, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Wed Nov 08 19:01:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394631, encodeId=30a61394631ef, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528343, encodeId=2b03152834326, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 11 11:01:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196325, encodeId=99f01963259e, content=TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Wed May 10 22:07:46 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-10 121485632188547785

    TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。

    0

相关资讯

Oncogenesis:二甲双胍可以抑制SUV39H1调控的前列腺癌细胞迁移

前列腺癌(PCa)是男性癌症相关死亡的主要原因,很大程度上是由于不能治愈的远距离转移。二甲双胍是一种广泛应用于抗糖尿病2型的药物,研究发现,该药能够减少癌症风险并且能取得更好的诊断最近,有研究人员发现,二甲双胍能抑制PCa细胞的迁移,而PCa细胞的迁移与肿瘤转移能力相关。发病机理和肿瘤进展与肿瘤细胞中基因的异常表达相关,主要是通过表观修饰,比如DNA甲基化和组蛋白修饰。研究人员发现,SUV39H

JCO:雄激素受体剪接变体与前列腺癌对恩扎鲁胺和阿比特龙耐药间的关系

雄激素受体在前列腺癌的发展中起着非常重要的作用,通过雄激素剥夺治疗来抑制雄激素受体成为转移性前列腺癌的起始治疗。大部分病人,对雄激素剥夺治疗会有反应,但是随后这部分病人会表现出不同形式的复发及出现去势抵抗性前列腺癌。现在已经清楚是雄激素受体通过增加表达及扩增在去势抵抗性前列腺癌中仍起驱动作用。使得雄激素受体在去势抵抗中起作用的另一机理,即通过肾上腺中的前体类固醇使得瘤内合成雄激素(睾酮或二氢睾酮)

Prostate Cancer P D:机器人辅助的根治性前列腺癌切除术治疗临床高风险前列腺癌病人的功能恢复

最近,研究人员评估了机器人辅助的根治性前列腺癌切除术(RARP)治疗临床高风险前列腺癌病人(PCa)的3年排尿控制(UC)和性功能(SF)恢复状况。2001年和2004年,研究人员对美国和欧洲的两个三级医疗中心维护的数据库,即769名患有D'Amico高风险PCa并且经历RARP的病人资料,进行了回顾性分析。研究人员分别利用术前和术后Cox比例风险回归模型对从RARP与UC和SF的恢复的时间关系进

Prostate Cancer P D:前列腺切除术后的补救放射疗法后,受益于雄激素阻断治疗的选择的男性

对于哪一名男性能够在前列腺切除术后补救放射疗法(SRT)中加入雄激素阻断治疗(ADT)受益最大,人们对这个问题仍旧不清楚。最近,有研究人员评估了ADT对SRT在前列腺切除术后具有增加的或者永久PSA男性的成功生存率(FFS)的影响。研究人员鉴定了在1987年到2010年,前列腺切除术后接受SRT的男性患者,并根据单个的SRT后失败的风险,利用独立递归分级指数(RPA)鉴定了有利的、中间的和不利的小

CLIN CANCER RES:前列腺切除术前新辅助Enzalutamide治疗

前列腺癌需要雄激素受体活化。理想的雄激素受体拮抗作用可以有效缩小局部病灶并抑制或清除微转移灶。CLIN CANCER RES近期发表了一篇文章,研究前列腺切除术前雄激素受体拮抗剂enzalutamide(enza)单独或与dutasteride(dut)及leuprolide联合新辅助治疗(enza/dut/LHRHa)的疗效。

Brit J Cancer:在外周血和前列腺癌风险中,染色体8q24 DNA甲基化的预期研究

染色体8q24表现为几种癌症的重要遗传敏感区域,包括了前列腺癌。然而,该区域的DNA的甲基化对癌症贡献的风险却所知甚少。最近,研究人员预期性的评估了8q24区域DNA甲基化与前列腺癌的关系,实验材料为利用从694名前列腺癌案例(包括172名恶性案例)的诊断前血样和703名在前列腺、肺、大肠和卵巢癌筛选临床实验中的对照,并利用逻辑回归评估让步比和95%置信区间。研究结果发现,在多项检验调整后,50个